VIIBRYD Drug Patent Profile

When do Viibryd patents expire, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viibryd

A generic version of VIIBRYD was approved as vilazodone hydrochloride by TEVA PHARMS USA on September 30^th, 2019.

Summary for VIIBRYD

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIIBRYD

Paragraph IV (Patent) Challenges for VIIBRYD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIIBRYD	Tablets	vilazodone hydrochloride	10 mg, 20 mg, and 40 mg	022567	5	2015-01-21

US Patents and Regulatory Information for VIIBRYD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-001	Jan 21, 2011	AB	RX	Yes	Yes
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011	AB	RX	Yes	No
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-003	Jan 21, 2011	AB	RX	Yes	No

International Patents for VIIBRYD

See the table below for patents covering VIIBRYD around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	153663
Australia	679774
Australia	7424494

Last updated: February 10, 2026

Investment Scenario and Fundamentals Analysis for Viibryd (Vilazodone)

Overview

Viibryd (vilazodone) is an antidepressant marketed by Takeda Pharmaceutical. It received FDA approval in January 20111 and is indicated for Major Depressive Disorder (MDD). The drug's mechanism combines serotonin reuptake inhibition with partial agonism at 5-HT1A receptors, distinguishing it within the selective serotonin reuptake inhibitor (SSRI) class. Despite initial market entry, Viibryd faces competitive challenges, limiting its sales potential and affecting future investment scenarios.

---

Market Position and Revenue Trajectory

Market Size & Growth

• The global antidepressant market was valued at $16.2 billion in 2021, projected to grow at a CAGR of 3.7% through 2028 (Source: Grand View Research).

• MDD affects approximately 4.4% of the global population, with higher prevalence among adults aged 18-64 (Source: WHO).

Viibryd's Market Share

• Estimated peak sales of Viibryd: Between $350-$500 million annually in the US, based on sales figures reported by Takeda between 2015-2019 (Sources: Takeda 2019 annual report).

• Competitors include Wellbutrin, Lexapro, and newer agents like Spravato (esketamine), which have gained market share since Viibryd’s launch.

Sales Performance

• Post-launch, Viibryd's US sales peaked at approximately $165 million in 2015, then declined to roughly $73 million in 2019 due to competition and market saturation (Sources: Takeda earnings reports).

• International sales remain limited, with approval in select countries.

Fundamentals and R&D Outlook

Patent and Exclusivity

• No current patent protection for Viibryd beyond initial patent, which expired or is expiring around 2021-2022.

• This exposes the drug to generic competition, eroding margins.

Pipeline and Lifecycle

• Takeda's pipeline includes other antidepressants and novel therapies, but no direct replacements for Viibryd announced.

• The drug’s limited pipeline integration and increasing generic threat reduce long-term revenue prospects.

Pricing and Reimbursement

• The drug is priced competitively within the antidepressant class, but reimbursement pressures and formulary exclusions limit payor coverage.

Regulatory and Legal Considerations

• No recent regulatory actions or litigations impacting Viibryd, but patent expiration creates a future risk.

Investment Risks

• Market Competition: The presence of multiple well-established SSRIs and SNRIs, along with newly launched agents, constrains sales.

• Patent Loss: Loss of exclusivity accelerates generic entry, eroding profit margins.

• Sales Decline: Revenue decline since 2015 indicates saturation and competitive displacement.

• Pipeline Limitations: Lack of a clear successor within Takeda’s pipeline restricts long-term growth opportunities from Viibryd.

Valuation and Investment Outlook

• Based on current sales and revenue trends, Viibryd offers limited growth prospects.

• A significant decline in revenue is forecasted post-generic entry, impacting valuation models.

• Niche positioning or repositioning strategies would be necessary to sustain long-term value.

• Overall, the asset presents limited upside unless significant market expansion or pipeline integration occurs.

---

Key Takeaways

• Viibryd has a limited sales trajectory constrained by patent expiration, competition, and market saturation.

• The drug's revenue peaked in 2015 and has since declined, with a downward trend expected to continue.

• Lack of a robust pipeline or exclusive positioning reduces its strategic investment appeal.

• Risks include generic competition and reimbursement pressures.

• Investors should consider the drug's diminishing market exclusivity and competitive landscape before valuation.

---

FAQs

1. What is the current patent status of Viibryd?
The primary patent protecting Viibryd expired or is close to expiration, leading to imminent generic entry, which is expected to significantly reduce sales.

2. How does Viibryd's efficacy compare with its competitors?
While Viibryd shows comparable efficacy to other antidepressants, its distinct mechanism offers limited additional benefits over established SSRIs, reducing its competitive advantage.

3. Are there any ongoing clinical trials for Viibryd?
Takeda has not announced continued development or new trials for Viibryd. The focus appears to have shifted toward pipeline products.

4. What is the outlook for Takeda's antidepressant portfolio?
Takeda's pipeline emphasizes novel mechanisms and combination therapies, with limited focus on Viibryd analogs. The loss of exclusivity diminishes Viibryd's strategic value.

5. Should investors consider Viibryd as a long-term hold?
Given its revenue decline, patent expiration, and competitive pressures, Viibryd is unlikely to serve as a long-term growth asset in a portfolio.

---

References

1. FDA. "Vilazodone hydrochloride (Viibryd) Prescription Information," 2011.
2. Grand View Research. “Antidepressant Market Size, Share & Trends Analysis,” 2022.
3. Takeda Pharmaceutical. Annual Reports, 2015-2019.
4. World Health Organization. “Depression Fact Sheet,” 2021.